Somerset, N.J. – November 8, 2016 — Catalent Pharma Solutions (Booth 901), the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, today announced it will host and present multiple industry-centric discussions, present scientific papers, and exhibit at the forthcoming 2016 American Association of Pharmaceutical Scientists (AAPS) Annual Meeting and Exposition, which runs from Nov. 13 -17, at the Colorado Convention Center, Denver, Colorado.
Catalent will also be showcasing its award-winning OptiForm® Solution Suite platform, designed to match the best, most innovative, drug delivery technologies to each developmental molecule, with the goal of providing optimal candidate formulations for animal PK studies in twelve weeks. This year, the technology been expanded to include macromolecules, and the identification of suitable non-invasive methods of drug delivery for biologically derived drug products.
On Monday, Nov. 14 at 9 a.m., Dr. Cornell Stamoran, Catalent’s Vice President of Strategy and Corporate Development, will chair "New Technologies and Techniques to Accelerate Early Development and Reduce Risk," a half day seminar with participants including Dr. Keith Horspool, Vice President of Development, Boehringer Ingelheim, Dr. Shaukat Ali, Technical Support Manager, BASF Corporation and Debra Bingham, Partner, Valeo Partners.Additionally, on Wednesday, Nov. 16, at 10 a.m., Dr. Ronak Savla, Catalent’s Scientific Affairs Manager, will take part in the debate, "Let’s (Not) Take a Stab at This: Non-invasive Macromolecule Delivery."
Throughout the show, Catalent will be hosting a number of "TECH Talks" at its in-booth Discovery Zone. These are short-format educational talks on subjects ranging from drug discovery through to development.
Catalent will also present 24 scientific posters at the AAPS meeting on a broad spectrum of topics, including use of lipid-based formulations, processing of sustained release formulations using a twin-screw extrusion process, in situ solubility screening via fiber optic assay: comparison with high-performance liquid chromatography, parallel screening approaches for the non-invasive delivery of macromolecules, and applying six sigma to analytical tech transfers.
A full list of poster topics and presentation times can be found at http://www.catalent.com/index.php/news-events/events/AAPS-2016.
To arrange a meeting with any of the Catalent team at AAPS, please contact Richard Kerns at NEPR - email@example.com.
Catalent is the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products. With over 80 years serving the industry, Catalent has proven expertise in bringing more customer products to market faster, enhancing product performance and ensuring reliable clinical and commercial product supply. Catalent employs approximately 9,500 people, including over 1,400 scientists, more than 30 facilities across five continents, and in fiscal 2016 generated $1.85 billion in annual revenue. Catalent is headquartered in Somerset, New Jersey. For more information, visit www.catalent.com